As first-line treatment for patients with advanced NSCLC harboring drug-sensitive EGFR mutations, previous clinical trials showed the effectiveness of epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib, erlotinib and afatinib [4,5,6,7,8,9]. Here, EGFR is linked to non-small cell lung carcinoma.